Cargando…

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer

PURPOSE: To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER(+)/HER2(−) breast cancer; and (ii) the pharmacodynamic effect of the agents on the biomarkers. EXPERIMENTAL DESIGN: 307 postmenopausa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dowsett, Mitch, Kilburn, Lucy, Rimawi, Mothaffar F., Osborne, C. Kent, Pogue-Geile, Katherine, Liu, Yuan, Jacobs, Samuel A., Finnigan, Melanie, Puhalla, Shannon, Dodson, Andrew, Martins, Vera, Cheang, Maggie, Perry, Sophie, Holcombe, Chris, Turner, Nick, Swift, Claire, Bliss, Judith M., Johnston, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Translational Cancer Mechanisms and Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632606/ https://www.ncbi.nlm.nih.gov/pubmed/34645649 http://dx.doi.org/10.1158/1078-0432.CCR-21-1628

Ejemplares similares

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
por: Denkert, Carsten, et al.
Publicado: (2023)

Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers
por: Gazinska, Patrycja, et al.
Publicado: (2022)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
por: Anwar, Munawar, et al.
Publicado: (2021)

Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases
por: Li, Jing, et al.
Publicado: (2022)

A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2023)

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2(+)/HR(−) Trial
por: Graeser, Monika, et al.
Publicado: (2023)

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
por: Arpino, Grazia, et al.
Publicado: (2023)

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
por: Cheng, Zhao, et al.
Publicado: (2022)

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
por: Xia, Youli, et al.
Publicado: (2022)

ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
por: Tang, Zhe, et al.
Publicado: (2021)

Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy
por: Levin, Noam, et al.
Publicado: (2021)

Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia
por: Ding, Yang-Yang, et al.
Publicado: (2021)

Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming
por: Simonetta, Federico, et al.
Publicado: (2021)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Memory-like Differentiation Enhances NK Cell Responses to Melanoma
por: Marin, Nancy D., et al.
Publicado: (2021)

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
por: Koh, Siang-Boon, et al.
Publicado: (2021)

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
por: Kim, Dae-Hwan, et al.
Publicado: (2021)

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
por: Miao, Yu Rebecca, et al.
Publicado: (2021)

Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER(+) Breast Cancer
por: Servetto, Alberto, et al.
Publicado: (2021)

IL13Rα2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases
por: Márquez-Ortiz, R. Alejandro, et al.
Publicado: (2021)

TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas
por: Gonzalez-Buendia, Edgar, et al.
Publicado: (2021)

DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
por: Venugopal, Kartika, et al.
Publicado: (2022)

Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
por: Carter, Jodi M., et al.
Publicado: (2021)

Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
por: Seeber, Andreas, et al.
Publicado: (2022)

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
por: Palmer, Adam C., et al.
Publicado: (2022)

Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
por: Hernandez, Sharia, et al.
Publicado: (2022)

Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
por: Sabbagh, Aria, et al.
Publicado: (2021)

Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
por: Hashimoto, Ayumi, et al.
Publicado: (2021)

Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma
por: Zhai, Lijie, et al.
Publicado: (2021)

Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer
por: Peng, Hui, et al.
Publicado: (2021)

The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma
por: Sharma, Neeraj, et al.
Publicado: (2021)

Targeting Podoplanin for the Treatment of Osteosarcoma
por: Takemoto, Ai, et al.
Publicado: (2022)

Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
por: Vesely, Clare, et al.
Publicado: (2022)

Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations
por: Shi, Qiong, et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
por: Sheehan, Beshara, et al.
Publicado: (2022)

DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
por: Kurani, Hetakshi, et al.
Publicado: (2022)

A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer
por: Dylgjeri, Emanuela, et al.
Publicado: (2022)

Targeting the Ubiquitin–Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer
por: Majeed, Safa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3f9g0dqvguq7tanvh2i9nft2cn